TIMI Study Group

Providing the latest news and research from the TIMI Study Group, an ARO affiliated with Brigham and Women’s Hospital and Harvard Medical School.

[TIMI Study Group @TIMIStudyGroup]

TIMI is proud to celebrate our 40th anniversary! Since 1984, we've been dedicated to advancing the knowledge and care of patients suffering from cardiovascular disease and its risk factors. View the 40th anniversary edition of the TIMI book, now online.
https://t.co/NXuasBCjV4

[TIMI Study Group @TIMIStudyGroup]

The TIMI family remembers Dr. Eugene Braunwald in 4 articles the current issue of @CircAHA @DrM_ODonoghue @EBohula
https://t.co/yVa0MNqxPc

[NEJM @NEJM]

Original Article: ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels (TYDAL-TIMI 78 trial) https://t.co/87oVeGSoJ6

#ScientificSessions26 | @AHAScience

[TIMI Study Group @TIMIStudyGroup]

ANGPTL4 inhibition appears to reduce triglycerides. Dr. Michelle O'Donoghue discusses the TYDAL-TIMI 78 trial Part A results.https://t.co/FfVRdPKsvj @DrM_ODonoghue #AHA

[TIMI Study Group @TIMIStudyGroup]

SD DOACs show a significant greater clinical benefit over warfarin in lower HDI countries and suggest that their actual clinical value may be higher in these settings. @rgiugliano #AHA26

[TIMI Study Group @TIMIStudyGroup]

TYDAL-TIMI 78 demonstrates that #ANGPLT4 inhibition leads to a dose-dependent drop in TG levels. Full study results now online in @NEJM. @DrM_Odonoghue #AHA26

[TIMI Study Group @TIMIStudyGroup]

https://t.co/xtTuQyXITQ

[TIMI Study Group @TIMIStudyGroup]

Among patients with diabetes or atherosclerosis, but without a prior MI or stroke, those with CKD are at high risk for CV outcomes and death. Intensive LDL-C lowering to ~45mg/dL with #evolocumab substantially attenuates this risk. See details online at @JACC. @ebohula #AHA26

[TIMI Study Group @TIMIStudyGroup]

Endothelial cell polygenic risk score association with CCTA-defined extensive coronary plaque is modified by LDL-C, suggesting a role for endothelial genetic susceptibility in LDL-related atherogenesis #AHA26

[TIMI Study Group @TIMIStudyGroup]

Among patients without overt #ASCVD, leukocyte telomere length polygenic score independently predicts CV events beyond clinical risk factors and CAD polygenic risk. #AHA26

[TIMI Study Group @TIMIStudyGroup]

If proven to be effective for stroke prevention in AF, FXI inhibition with #abelacimab may be particularly advantageous in high-risk patients with AF and history of bleeding #AHA26

[TIMI Study Group @TIMIStudyGroup]

TIMI research fellow Mahmoud Shams presents his project on the HDI and global outcomes with DOACs vs warfarin in COMBINE-AF, tomorrow at 12:15 in Moderated Digital Poster 23, Population Science Zone @rgiugliano #AHA26

[TIMI Study Group @TIMIStudyGroup]

See @SidPatelMD present his SMART-C poster "SGLT2 Inhibitors and Incident Atrial Fibrillation", tomorrow at 10:45 in Moderated Digital Poster 2, Clinical Science Zone 1 #AHA26

[TIMI Study Group @TIMIStudyGroup]

Team involvement was assoc w/ ↑ cardiogenic shock severity & more advanced MCS use, yet adjusted in-hospital mortality was similar. These findings highlight wide differences in how hospitals use shock teams & the need to understand which strategies improve outcomes. #AHA26

[TIMI Study Group @TIMIStudyGroup]

In 24 hours, @DrM_Odonoghue presents the LBCT results of the TYDAL-TIMI 78 trial, Center Stage, North Hall, Level 3 #AHA26

[TIMI Study Group @TIMIStudyGroup]

Dr. David Morrow is a panelist in the session, "Critical Care Cardiology: An International Perspective", tomorrow at 3:30 in S405B #AHA26

[TIMI Study Group @TIMIStudyGroup]

Jan Cornel presents the VESALIUS-CV (TIMI 66) work on #evolocumab in patients with chronic kidney disease, in 24 hrs in N231 @ebohula #AHA26

[TIMI Study Group @TIMIStudyGroup]

TIMI biostatistician Dr. Yi-Pin Lai presents her work on a leukocyte telomere length PRS for CAD, tomorrow at 3:15 in Moderated Digital Poster 27, Basic Science Zone #AHA26

[TIMI Study Group @TIMIStudyGroup]

Interventional radiologist Dr. Milena Petranovic speaks on endothelial cell polygenic risk and CAD on coronary CT angiography, in 24 hours in Moderated Digital Poster 27, Basic Science Zone #AHA26

[TIMI Study Group @TIMIStudyGroup]

Among patients with atherosclerosis or high-risk diabetes, but without a history of prior stroke, intensive LDL-C lowering with #evolocumab down to ~45 mg/dL reduced the incidence of a first stroke in the VESALIUS-CV study. @ebohula #AHA26

[TIMI Study Group @TIMIStudyGroup]

See Dr. Mahmoud Shams present his work on history of bleeding and safety of #abelacimab vs rivaroxaban in AZALEA-TIMI 71, tomorrow at 11:50 in Moderated Digital Poster 3, Clinical Science Zone 1 #AHA26